Multiple Sclerosis Drugs - Southern Europe

Southern Europe

In Southern Europe, the Multiple Sclerosis Drugs market is anticipated to witness a significant growth in revenue, with projections indicating a substantial increase to reach US$0.75bn in 2024.
This growth is expected to continue at an annual growth rate (CAGR 2024-2029) of 0.53%, leading to a market volume of US$0.77bn by 2029.
When compared on a global scale, it is worth noting that United States is expected to generate the highest revenue in the Multiple Sclerosis Drugs market, with an estimated value of US$11,770.00m in 2024.
In Southern Europe, the demand for new and innovative Multiple Sclerosis drugs is steadily increasing, with Spain emerging as a key market player.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The market for Multiple Sclerosis Drugs in Southern Europe has been experiencing significant growth in recent years.

Customer preferences: Patients with Multiple Sclerosis in Southern Europe are increasingly looking for drugs that provide long-term symptom relief, without causing significant side effects. They also prefer drugs that are easy to administer and have a low frequency of dosing.

Trends in the market: There has been a significant increase in the number of drugs available for the treatment of Multiple Sclerosis in Southern Europe in recent years. This has led to increased competition among drug manufacturers, which has resulted in lower prices for patients. Additionally, there has been a trend towards the development of drugs that target specific types of Multiple Sclerosis, such as relapsing-remitting Multiple Sclerosis.

Local special circumstances: Southern Europe has a high prevalence of Multiple Sclerosis, which has contributed to the growth of the market for Multiple Sclerosis Drugs in the region. Additionally, the healthcare systems in Southern Europe are well-developed, which has led to increased access to healthcare for patients with Multiple Sclerosis.

Underlying macroeconomic factors: The economic growth in Southern Europe has been slow in recent years, which has led to increased pressure on healthcare budgets. This has resulted in a greater focus on cost-effectiveness in the healthcare sector, which has led to increased competition among drug manufacturers and lower prices for patients. Additionally, the aging population in Southern Europe has contributed to the growth of the market for Multiple Sclerosis Drugs, as the prevalence of Multiple Sclerosis increases with age.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.